|
Catalogue
Number
|
Product
|
Order number / Unit
|
|
|
9775
|
Lu-DOTA-TATE
|
9775.0001: 1 mg per vial
9775.0010: 10 mg per vial
Please inquire for customized
filling and bulk quantities.
|
|
|
Reference standard for 177Lu-DOTA-TATE
|
|
|
|
|
|
|
|
|
Molar Mass: 1607.57
|
|
|
C65H187LuN14O19S2 (net peptide)
|
|
|
CAS-RN not yet assigned
|
|
|
[177Lu]DOTA-TATE: [753443-19-5]
|
|
|
Colourless to off-white freeze-dried solid packaged in dark glass screw cap vials.
|
|
|
|
|
|
|
|
|
Purity: ≥ 95 %
|
|
|
Certificates:
CoA; MS (identity) and HPLC (purity)
|
|
|
Chemical Name:
Lutetate(1-)-, [N-[[4,7,10-tris[(carboxy-κO)methyl]-1,4,7,10-tetraazacyclododec-1-yl-κN1,κN4,κN7,κN10]acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threonine cyclic (2→7)-disulfidato(4-)]-
|
|
|
Synonymes:
Lu-DOTATATE; Lu-DOTA-[Tyr3]octreotate
|
|
|
Literature:
1. De Jong M. et al. [177Lu-DOTA0,TYR3]Octreotate for Somatostatin Receptor-Targeted Radionuclide Therapy. Int. J. Cancer. 2001, 92, 628-633.
|
|
|
2. Kwekkeboom D.J. et al. [177Lu-DOTA0,Tyr3]octreotate: comparison with [111In]-DTPA0-octreotide in patients. Eur. J. Nucl. Med. 2001, 28, 1319-1325.
|
|
|
|
|
|
|
|
|
|
|
|
date of product catalogue issue:
05 April 2012
|